Literature DB >> 748018

Identification of a tripeptidyl aminopeptidase in the anterior pituitary gland: effect on the chemical and biological properties of rat and bovine growth hormones.

T W Doebber, A R Divor, S Ellis.   

Abstract

The NH2-terminal heterogeneity which is generated in bovine GH during its extraction from mildly acidified pituitary homogenates is attributable to a newly identified peptidase. The beta-naphthylamide of Phe-Pro-Ala, modeled after the NH2-terminal tripeptide sequence of the phenylalanyl monomer of bovine growth hormone, was cleaved by the peptidase into the tripeptide and B-naphthylamine and served as a substrate for assay of the eznyme. However, the B-naphthylamide of Ala-Phe-Pro, modeled after the NH2-terminal tripeptide sequence of the alanyl monomer, was not cleaved. In harmony with this specificity, the peptidase cleaved 11 tripeptides sequentially from the NH2-terminus of the phenylalanyl monomer of bovine GH but none from the alanyl monomer. Six of the tripeptides nearest the NH2-terminus were unequivocally identified and their sequences were consistent with the NH2-terminal octadecapeptide sequence of the phenylalanyl monomer of bovine GH. Five additional peptides were by composition consistent with their being tripeptides derived from residues 19--33. Because of the apparent specificity for the hydrolytic release of tripeptides and inability to cleave substituted tripeptidyl derivatives, the enzyme is considered to be a tripeptidyl aminopeptidase. In its hydrolysis of phenylalanyl monomers of rat growth hormone, a similar number of tripeptides was released, associated with which there was a 70% loss of biological activity but no reduction in immunological activity. The enzyme could be solubilized by extraction with 1% Triton X-100 at pH 3.0, precipitated between 2 and 3 M (NH4)2SO4, and further purified by gel filtration on G-75 in M/10 acetic acid. The enzyme has a mol wt of 57,000 and is optimally active at pH 4. It can be differentiated from cathepsin D by its insensitivity to inhibition by pepstatin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 748018     DOI: 10.1210/endo-103-5-1794

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   5.051


  6 in total

1.  Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis.

Authors:  L Lin; P Lobel
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

2.  Aminopeptidase activity in the brains of mice with chronic Toxoplasma gondii infections.

Authors:  S Akao; K Yamakami; M Nishiyama; M Tanaka
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

3.  Active site of tripeptidyl peptidase II from human erythrocytes is of the subtilisin type.

Authors:  B Tomkinson; C Wernstedt; U Hellman; O Zetterqvist
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Is there a tripeptidyl peptidase in the renal brush-border membrane?

Authors:  A J Kenny; J Ingram
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

5.  Dipeptidyl-peptidase I does not functionally compensate for the loss of tripeptidyl-peptidase I in the neurodegenerative disease late-infantile neuronal ceroid lipofuscinosis.

Authors:  Kwi-Hye Kim; Christine T Pham; David E Sleat; Peter Lobel
Journal:  Biochem J       Date:  2008-10-15       Impact factor: 3.857

6.  Potential pitfalls and solutions for use of fluorescent fusion proteins to study the lysosome.

Authors:  Ling Huang; Douglas Pike; David E Sleat; Vikas Nanda; Peter Lobel
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.